Accentia at buy by Jefferies

Accentia Biopharmaceuticals Inc. was reiterated at buy and given a $9 price target by Jefferies & Co., Inc. analyst Adam Walsh based on the company's pipeline progress. Jefferies believes SinuNase and BiovaxID are late-stage products addressing underserved markets overlooked by the Street. The company's GAAP loss per share of $0.35 was one cent lower than Jefferies' estimate. Shares of the Tampa, Fla., biopharmaceutical company were up $0.02, or 0.35%, at $5.69 on volume of 66,158 shares versus the three-month running average of 26,229 shares. (Nasdaq: ABPI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.